Phagenesis

Phagenesis is a commercial-stage medical device company addressing the significant unmet need of post-stroke dysphagia with its Phagenyx System. The device delivers targeted pharyngeal electrical stimulation (PES) to sensory nerves, promoting neurologic recovery of swallowing function. Backed by over 30 publications and recent inclusion in the AHA/ASA stroke guidelines, the technology has demonstrated in clinical studies the ability to reduce aspiration risk, speed return to oral nutrition, and significantly shorten hospital and ICU stays. The company is positioned to transform post-stroke care by offering an evidence-based, non-disruptive intervention for a condition with high morbidity, mortality, and economic burden.

Pharyngeal Electrical Stimulation (PES) delivered via a catheter-based system to stimulate sensory nerves in the pharynx, promoting neuroplasticity and recovery of swallowing control after neurological injury.

The competitive landscape for a device directly promoting neurological recovery in dysphagia is relatively sparse. Current standard of care involves behavioral therapy and compensatory strategies from speech-language pathologists, with few other FDA-cleared neurostimulation devices. Phagenyx's primary competition is the entrenched, low-tech status quo, but it may face future competition from other neuromodulation or pharmaceutical approaches.